This analysis compares the regimen-related toxicity (RRT) and overall non-relapse mortality (NRM) in Hodgkin's disease patients conditioned with either CBV (cyclophosphamide, BCNU (carmustine), and VP16-213 (etoposide)) (26 patients) or CBVP (CBV + cisplatin) (68 patients) followed by autologous stem cell transplantation (ASCT). CBVP included a continuous infusion rather than intermittent doses of etoposide, a lower BCNU dose and the addition of cisplatin. RRT and NRM were determined for each regimen and compared; risk factors for each were examined by multivariate analysis. Grade IV (fatal) RRT occurred in five patients (pulmonary in two, cardiac in two, and central nervous system in one). Eighteen patients experienced grade II-III pulmonary RRT, consistent with BCNU damage in 15. Prior nitrosourea exposure was the main risk factor for pulmonary RRT. Grade II mucosal and hepatic RRT occurred less often after CBVP vs CBV (P = 0.031 and 0.0003, respectively). In addition, three other early and eight late non-relapse deaths were seen. Median follow-up of the entire group is 5.1 (range 2.8-10.2) years. The probability of overall NRM was 26% (95% confidence interval (CI) 13-50%) with CBV vs 23% (95% CI 12-41%) with CBVP (P = 0.40). The progression-free survival and relapse rates were similar. Although the rates of fatal RRT, pulmonary RRT and overall NRM were similar with CBV or CBVP, CBVP produced less mucosal and liver RRT with a comparable antitumor effect. As many autografted patients are cured, future efforts should include measures to decrease NRM.
High-dose chemotherapy (HDCT) followed by autologous hematopoietic stem cell transplantation (ASCT) produces long-term progression-free survival (PFS) in up to 50% of patients with Hodgkin's disease that has progressed after primary chemotherapy. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] Since the prior chest radiotherapy that many patients have received predisposes to interstitial pneumonitis when total body irradiation is used, 3, 19 most centers have used conditioning regimens containing only chemotherapy. One of the most commonly used conditioning regimens is CBV (cyclophosphamide, BCNU (carmustine) and VP16-213 (etoposide)). The term CBV does not describe a single regimen, however, since the doses and schedules of the agents utilized have varied among transplant centers. 1, 2, 9, 12, [14] [15] [16] 18 Since 1985, we have utilized CBV regimens at doses higher than those originally described 1 and currently used by some transplant centers 9, [14] [15] [16] in an attempt to achieve greater tumor cytoreduction. 5, 12, 13 Patients were entered on to transplant protocols at the first evidence of disease progression, if possible, since we postulated that such higher dose CBV regimens would be better tolerated in patients with less prior conventional therapy. These protocols used specific brief cytoreductive reductive measures, without further restaging, prior to HDCT and ASCT as part of the overall transplant program.
Between March 1985 and May 1992, 94 patients with Hodgkin's disease were treated with one of two conditioning regimens -CBV or CBV with the addition of cisplatin (CBVP), followed by ASCT. 12, 13 This analysis will focus on the incidence of RRT and overall NRM among the 94 patients who received these conditioning regimens.
Patients and methods

Eligibility criteria
Eligibility criteria included the following: (1) progressive Hodgkin's disease after multi-agent chemotherapy given with curative intent; (2) presumed low probability of cure with further conventional therapy, specifically excluding patients with localized recurrences potentially curable with radiotherapy; (3) age Ͻ61 years; (4) no evidence of marrow involvement with Hodgkin's disease at the time of marrow harvest, or adequate peripheral blood stem cell (PBSC) collection; (5) absence of severe co-morbid illness; (6) informed consent. These patients were treated on protocols approved by the Institutional Review Boards at the British Columbia Cancer Agency, University of British Columbia and Vancouver Hospital and Health Sciences Center.
Exclusions
Five patients did not receive CBV or CBVP per protocol during the study period. The reasons for their exclusion included protocol violation (one patient), interruption of CBV conditioning due to problems with marrow viability (one patient), brief participation in another multi-institutional study 20 (two patients) and omission of BCNU due to severe pre-existing pulmonary dysfunction (one patient).
Patient characteristics
The characteristics of the 94 patients entered on to the transplant protocol are listed in Table 1 . Seventy-six patients had received combinations of MOPP/ABV(D) as initial chemotherapy, and all but 10 had received MOPP and ABV(D) at some time. Thirty-five patients had received prior radiation therapy, which included the chest in 34 patients. Most patients were entered on to protocol at the time of first relapse and had received a median of one (range 1-6) prior regimens. As shown in Table 2 , the majority of patients then received specific conventional cytoreductive therapy before HDCT, which included two cycles of mechlorethamine, vinblastine, procarbazine and prednisone (MVPP), 21 involved-field radiation therapy (IF-RT), or both modalities as previously described. 12, 13 Therefore, the median number of prior regimens at the time of ASCT was two (range 2-7). Patients were not formally restaged after conventional cytoreductive therapy, so that chemosensitivity status was not determined. All patients entered on to protocol proceeded to ASCT.
Two patients with active bone marrow involvement received PBSC transplants using cells collected after conventional chemotherapy while eight patients who had failed induction chemotherapy or who had active marrow involvement at the time of disease progression received high-dose cyclophosphamide (7 g/m 2 ) (HD-CY) over 4 days, with or without GM-CSF, as priming therapy for PBSC collection.
Transplant features and conditioning regimens
Drug doses were calculated on the basis of the lower value of ideal or actual body weight. The first 26 patients received CBV, consisting of cyclophosphamide 1.8 g/m 2 intravenously (i.v.) over 2 h daily on days −7 to −4; VP16-213 0.4 g/m 2 i.v. over 1 h every 12 h on days −7, −6 and −5; and BCNU 0.6 g/m 2 i.v. over 2 h on day −3 (Figure 1 ). Beginning in January 1988, this regimen was modified, in an attempt to decrease mucosal and lung toxicity while preserving the antitumor effect. Sixty-eight patients received the new CBVP regimen in which the same dose of cyclophosphamide was administered on days −6 to −3. The total dose of VP16-213 remained the same but the drug was given as a continuous 34-h i.v. infusion beginning on day −7 as previously described. 20 Cisplatin was added in conventional doses of 50 mg/m 2 i.v. on days −7, −6 and −5 while the dose of BCNU was reduced to 0.5 g/m 2 ( Figure  1 ). Cryopreserved stem cells were thawed and reinfused on day 0, except when volume considerations necessitated division of reinfusion on days 0 and 1.
The transplant-related characteristics of all 94 patients are summarized in Table 2 . Post-transplant hematopoietic growth factors were given to 26 patients treated after 1990.
Supportive care
Patients were hospitalized in single rooms with highefficiency particulate air (HEPA) filtration. An indwelling central venous silastic catheter was placed in all patients. Blood products were irradiated to у1500 cGy and were given to maintain a hemoglobin level у90 g/l and platelet count у20 × 10 9 /l. Empiric broad-spectrum antibiotics, anti-fungal therapy and total parenteral hyperalimentation were used as indicated. Uroprophylaxis consisted of hyperhydration.
Definitions
Regimen-related toxicity (RRT) due to the CBV or CBVP conditioning regimen was graded using the criteria of Bearman et al, 22 except that the evaluation of pulmonary toxicity was extended to day 150 post-transplant to encompass the development of delayed toxicity, similar to our previous description. 23 In general, grade I RRT was minor and reversible without specific therapy; grade II toxicity required medical intervention; grade III toxicity was lifethreatening; and grade IV toxicity was fatal. Non-relapse mortality (NRM) referred to death from any cause other than Hodgkin's disease, including RRT, and was calculated from the date of transplant. PFS was calculated from the date of transplant until the date of progression, death from non-relapse causes, or if progression-free, to the date of last follow-up.
Statistical analysis
Characteristics of the patients receiving CBV or CBVP were compared using the Pearson chi-square test. This method was also utilized to evaluate differences in RRT between the two conditioning regimens in each of the eight organ systems assessed. Logistic regression was used to determine prognostic factors for hepatic and mucosal RRT. The Cox proportional hazards model was used in assessing the relationship of variables to pulmonary RRT and NRM. In addition to conditioning regimen, variables examined included age, sex, disease status, initial stage, initial chemotherapy, prior number of drugs and regimens, extranodal disease at diagnosis and protocol entry, 'B' symptoms and Karnofsky performance status at diagnosis and protocol entry, prior radiotherapy, relapse in the irradiated field, type of pre-ASCT conventional cytoreduction, type of stem cell support, and the use of post-ASCT growth factors. The probability of pulmonary RRT, NRM, relapse and PFS were calculated from the day of transplantation (day 0) using the product-limit method of Kaplan and Meier, 24 and 95% confidence intervals (CI) were based on the log (log) transformation of the survival estimate.
Results
Comparison of patient characteristics
The comparative characteristics of patients receiving CBV or CBVP and shown in Tables 1 and 2 . The only significant differences were that more CBVP patients were Ͼ40 years of age (P = 0.013), had 'B' symptoms at diagnosis (P = 0.032), were given hematopoietic growth factors post-BMT (P = 0.0002), and were less frequently in a chemoresistant relapse at the time of protocol entry (P = 0.022).
RRT grading
The RRT grade by organ system and regimen is summarized in Table 3 . The incidence of life-threatening or fatal toxicity (grades III or IV) did not differ by conditioning regimen. The only differences observed were in the incidence of grade II mucosal and liver toxicity as outlined below. Pulmonary RRT, characterized by several distinctive clinical features, was the most common potentially serious toxicity seen with both regimens.
Fatal RRT: Grade IV RRT was seen in five patients (Table  3) . Two recipients of CBV died of RRT, one on day 18 due to CNS toxicity in the form of unexplained cerebral edema and the other on day 133 due to progressive interstitial lung disease. Three patients given CBVP died of either cardiac failure (two patients on days 0 and 3) or pulmonary hemorrhage (one patient on day 16). None of these patients had received HD-CY as priming therapy.
Life-threatening RRT:
As shown in Table 3 , grade III toxicity was relatively uncommon during the early post-transplant period. Two CBVP patients had grade III renal RRT (dialysis-dependent renal failure) and died of other toxicity (cardiac RRT in one and pulmonary hemorrhage in the other). Four patients had grade III pulmonary RRT (three after CBV and one after CBVP). Among these cases, three patients initially had reversible interstitial changes Table 3 Regimen-related toxicity
Organ system
Grade P value
Grade of toxicity by organ system in patients receiving conditioning with CBV (n = 26) or CBVP (n = 68) before ASCT. The number of affected patients is listed for each category, with the percentage in parenthesis.
described more fully below, while the fourth, who succumbed to CNS toxicity as described above, required intubation for lung toxicity as well as for obtudation. Of note, grade уIII hepatic toxicity was not seen in this analysis.
RRT by organ system
Mucosal RRT: The incidence of Grade II mucositis was 54% in patients conditioned with CBV compared to 26% in patients receiving CBVP (P = 0.031) ( Table 3) . Multivariate analysis confirmed the importance of conditioning regimen in this difference (P = 0.03) and also identified both prior chest radiation therapy (P = 0.0001) and stage III or IV disease at diagnosis (P = 0.007) as additional independent risk factors.
Hepatic RRT: Although hepatic toxicity was not lifethreatening in any patient, 14% of all patients experienced grade II hepatotoxicity; only two patients (2%) met the more stringent definition ('Jones' criteria) for hepatic venoocclusive disease. 25 Rather, most patients with hepatotoxicity had reversible elevations of transaminases with or without weight gain. Thirty-five percent of the patients treated with CBV developed grade II hepatic RRT compared to only 6% of patients given CBVP (P = 0.003) ( Table 3 ). Multivariate analysis indicated that the use of the CBV regimen was the only significant risk factor for grade II hepatic toxicity.
Pulmonary RRT: According to the Bearman criteria, grade II pulmonary RRT is defined as chest radiograph changes or Ͼ10% decrease in p0 2 not requiring Ͼ50% supplemental 0 2 or mechanical ventilation, while grade III RRT consists of interstitial changes requiring mechanical ventilator support or Ͼ50% oxygen by mask. Three patients developed early pulmonary hemorrhage and/or ARDS of uncertain etiology. This occurred a median of 8 (range 8-15) days posttransplant and was grade II in two patients and grade IV in one patient.
Seventeen patients manifested a different clinical pattern of pulmonary toxicity, consisting of a syndrome of dyspnea, associated with restrictive changes on pulmonary function testing and/or radiographic infiltrates, which developed a median of 57 (range 32-150) days after ASCT. This relatively delayed form of pulmonary RRT was grade II in 14 patients, grade III in two patients and grade IV in one patient. All patients with grades II and III toxicity had initial improvement in their pulmonary signs and symptoms. The pattern of toxicity was consistent with previously described BCNU lung damage. 26, 27 Four of these patients had been conditioned with CBV, while 13 had received CBVP.
The incidence of grades II-IV pulmonary RRT among all patients was 21% and did not differ significantly between the two conditioning regimens (P = 0.98). However, multivariate analysis identified prior nitrosourea exposure as the strongest risk factor for pulmonary RRT (P = 0.001); extranodal disease at diagnosis was identified as another predictive factor (P = 0.028). There was no significant relationship between pulmonary RRT and prior bleomycin lung toxicity or chest radiotherapy given either prior to protocol entry or as part of pre-conditioning cytoreductive therapy. The incidence of pulmonary RRT was 20.5% in patients who had never received chest radiotherapy compared with 17.6% in those who had received chest radiotherapy in the past and 27.3% in those who had been given IF-RT to the chest just before ASCT (P = 0.68).
Management of pulmonary RRT
All the patients experiencing early pulmonary hemorrhage or ARDS received steroids; one recovered, one died of CNS RRT and one succumbed to pulmonary failure. The management of the 17 patients with BCNU lung toxicity became more aggressive during the 7-year study period. In our hands, the optimal therapy for these patients involved the prompt institution of prednisone at a dose of 2 mg/kg per day at the first sign of dyspnea, after an infectious etiology had been excluded. Steroids were then tapered over 6-8 weeks. None of the initial four patients who developed this toxicity after CBV received corticosteroids early after onset of symptoms, although all were eventually treated. All four died of progressive pulmonary damage -one early and three late post-ASCT. None of the patients who developed BCNU lung toxicity after CBVP died of progressive lung disease. Twelve of these 13 received immediate corticosteroids, with rapid resolution of pulmonary abnormalities. The other, who had minimal grade II findings, recovered without specific therapy. Due to the improved management of pulmonary RRT over time, the relationship between conditioning regimen and mortality due to progressive pulmonary fibrosis after RRT could not be assessed accurately.
NRM
Three other early non-relapse deaths occurred before day 150 due to causes not directly classifiable as RRT -one due to infection (day 7), one due to pulmonary hypertension (day 62), and one due to marantic endocarditis (day 72). Including the five RRT-related deaths, the overall early NRM was 8% -three of 26 patients conditioned with CBV (11%) and five of 68 receiving CBVP (7%). Late NRM occurred due to pulmonary fibrosis in three patients (days 152, 723, 739), pneumonia in one (day 261), a motor vehicle accident in one (day 1584) and second malignancies in three, specifically brain tumor, gastrointestinal cancer and acute myelogenous leukemia (AML) on days 1125, 1688 and 1783, respectively. Median follow-up of all patients was 5.1 years -7.7 (range 4.7-10.2) years for patients conditioned with CBV and 4.7 (range 2.8-7.0) years in those receiving CBVP. The probability of NRM from all causes was 26% (95% CI 13-50%) with CBV vs 23% (95% CI 12-41%) with CBVP (P = 0.397).
Multivariate analysis of overall NRM identified three significant risk factors -prior bleomycin lung toxicity (P = 0.003), prior BCNU exposure (P = 0.005) and prior chest radiotherapy at any time before transplantation (P = 0.039).
Relapse
Nine relapses have occurred among patients conditioned with CBV and 17 among those receiving CBVP. The relapse probabilities were 43% (95% CI 25-66%) and 36% (95% CI 25-51%), respectively (P = 0.62).
PFS
The PFS for patients receiving CBV was 42% (95% CI 23-60%) compared with 50% (95% CI 38-61%) in those receiving CBVP. These differences were not significantly different (P = 0.43).
Discussion
In our experience, approximately 45% of all patients who have undergone ASCT for recurrent or relapsed Hodgkin's disease after chemotherapy remain free of disease progression. These patients were conditioned for ASCT with one of two CBV-based regimens using doses of the chemotherapeutic agents at the higher end of the range in current clinical practice. The two regimens differed in the administration schedule of etoposide, the dose of BCNU and the use of cisplatin.
Our analysis did not disclose any significant differences between the two regimens with regard to severe or fatal RRT or overall NRM. However, grade II mucosal and hepatic RRT occurred less frequently in patients treated with the CBVP regimen. Multivariate analysis confirmed the importance of the conditioning protocol in these differences. Patient tolerance of conditioning regimens, particularly with respect to mucositis, has become critical with the need to reduce resource utilization and the evolution of outpatient ASCT programs. 28 Although it is unclear which of the changes improved the RRT profile, the administration of etoposide by continuous intravenous infusion was likely to have been the most important factor in reducing mucositis. 20 In addition, two other factors contributing to mucosal toxicity were identified. Subclinical mucosal damage related to prior exposure to chest radiation, which commonly includes the cervical area in Hodgkin's disease patients as part of the mantle field, might explain the predisposition for mucosal toxicity in these patients. However, the increased risk of mucositis in patients previously exposed to nitrosoureas is not readily explainable.
The absence of severe hepatotoxicity after these two higher-dose CBV-based regimens is notable. The regimen from Seattle reported by Weaver et al 29 used drug doses similar to those in our CBV regimens and was associated with a high risk of grade III or IV hepatic toxicity (16%). Although the order of drug administration in the conditioning regimens differed, differences in patient selection probably accounted for this difference. In the Seattle experience, which also included patients with other lymphoid malignancies, all had received prior liver or mediastinal radiation or had a history of radiation toxicity.
Pulmonary RRT was the main non-hematologic toxicity observed in our patients. Although several patients developed pulmonary hemorrhage or ARDS early post-ASCT as previously described, 30 pulmonary toxicity usually occurred several weeks later and was consistent with BCNU lung damage. Worrisome features of this toxicity included its insidious onset in most patients, as well as the observation that patients with grade II or III RRT who were not treated with steroids could initially improve but later develop progressive fatal pulmonary fibrosis. In contrast to the experience of others, neither prior chest radiation therapy nor prior bleomycin lung toxicity were statistically associated with a significant increased risk of pulmonary RRT. 29, 31 It is not clear why the presence of extranodal disease at diagnosis was a risk factor for this toxicity. On the other hand, the identification of prior nitrosourea exposure as a risk factor for pulmonary RRT provides potentially useful clinical information.
The relationship of prior nitrosourea therapy and acute lung toxicity post-ASCT is not well understood. A BCNU dose Ͼ1050 mg/m 2 given with marrow support is associated with a high incidence of pulmonary toxicity. 26 Jones et al 27 have described a relationship between the pharmacodynamics of high-dose BCNU (600 mg/m 2 ), which vary among patients, and acute lung damage and have postulated that exposure to potentially toxic metabolites of BCNU might be responsible for this complication. Also, high total cumulative doses of BCNU given over a relatively long period of time can result in late fatal pulmonary fibrosis in patients with other malignancies. 32 Perhaps prior conventional-dose BCNU can produce a cumulative adverse effect on the lung, analogous to the effect of anthracyclines on the heart, leading to susceptibility to pulmonary injury after CBV or CBVP.
A reduction in the dose of BCNU in the conditioning regimen from 600 mg/m 2 to 500 mg/m 2 did not, as we had hoped, reduce the incidence of pulmonary toxicity. The finding that patients receiving high-dose BCNU may exhibit variable pharmacodynamics 27 may explain the lack of benefit of our dose reduction. On the other hand, comparison of CBV and CBVP toxicity is potentially constrained by our sample size. The statistical power of the comparison estimated that there was a 50% chance of detecting a 20% difference of toxicity, between the CBV and CBVP regimen. Therefore, clinically important differences in pulmonary toxicity could have been missed. However, the work of other investigators suggests that the risk of BCNU-related lung toxicity increases when the BCNU dose in the conditioning regimen exceeds 450 mg/m 2 , 26, 33, 34 and it is likely that both of our conditioning regimens were over the 'threshold' dose of this agent. At any rate, we feel that CBV regimens using у500 mg/m 2 doses of BCNU must be given with a high level of awareness of the risk of pulmonary toxicity and a low threshold for early institution of corticosteroid therapy if pulmonary symptoms develop. These regimens should be given with great caution in patients previously exposed to nitrosoureas.
Although prior chest radiotherapy and prior bleomycin lung toxicity were not predictive for the development of pulmonary RRT post-transplant, these two factors, in addition to prior nitrosourea exposure, were identified as risk factors for overall NRM. All these factors are related to the extent of prior cytotoxic therapy. The number of prior regimens did not correlate with the risk of NRM probably because the majority of these patients were entered into study after only one full initial regimen and, before HDCT and ASCT, an additional two cycles of brief cytoreduction. Other analyses of Hodgkin's disease patients also suggest that NRM is lower in patients transplanted earlier in their disease course 35, 36 and we feel that higher dose CBV regimens are associated with less NRM when used in minimally pretreated patients.
The overall early NRM observed in this series was 8%, a rate in the range of that reported by other centers using a number of different conditioning regimens. However, in general, the risk of early NRM in Hodgkin's disease patients has a trend downwards from 10-20% in some of the earlier studies 4, 5, 7, 8, 10 to 5-10%, or even lower, in more recent studies. 12, 14, 18 In particular, several series using lower-dose CBV regimens have reported very low early NRM rates, on the order of 0-5%. [15] [16] [17] Better supportive care measures, such as the use of hematopoietic growth factors and mobilized blood progenitor cells for autografting, as well as institutional experience, probably account for this trend. 37 Most of our patients were transplanted before 1990 and newer supportive care measures were unavailable. Nevertheless, early NRM decreased from 11% with the initial patients receiving CBV to 7% in the subsequent patients receiving CBVP.
Our study does not address the important question of the comparative antitumor effect of higher and lower CBV dose ranges, particularly in view of the somewhat greater early NRM seen with the higher doses. Specifically, there are no data available to judge definitively whether such higher doses produce lower relapse rates and better PFS and overall survival rates in patients with similar characteristics, such as extent of prior therapy and disease status.
Finally, late NRM has been increasingly recognized as transplanted patients have been followed for longer periods of time. In the current series, late NRM occurred in eight patients and was related to infection, pulmonary fibrosis and secondary cancers. Other studies of ASCT in Hodgkin's disease studies have reported similar causes of late fatal complications. The raw incidence of late fatal infections has ranged from 0.5-3% in other series; bacterial, viral and fungal pathogens have all been implicated. 7, 9, 11, 14, 16, 17, 38 The relative contributions of the known T cell defects in this disease 39 and of post-transplant immunodeficiency 40 are unclear. Many studies also report the occurrence of late fatal pulmonary toxicity after ASCT in a small proportion of patients. 9, 11, 14, 17 Several factors are probably involved, although in our series, this complication occurred as a delayed manifestation of BCNU toxicity early in our experience. However, the most worrisome late complication after ASCT has been the development of secondary cancers.
Risk factors for the development of secondary malignancies after ASCT are not yet well-defined. The cumulative incidence of secondary AML or myelodysplasic syndrome (MDS) post-ASCT has ranged from 4-14% in several studies of Hodgkin's disease patients. [41] [42] [43] [44] One recent study has evaluated patients who developed post-ASCT MDS characterized by a cytogenetic abnormality for which a florescence in situ hybridization (FISH) probe was available. The FISH probe was then used to analyze pre-ASCT specimens of bone marrow or PBSCs. Of interest, the majority of cases had the same cytogenetic abnormality detectable by FISH before transplant. 45 Thus, the transforming event was likely related to bone marrow damage from prior conventional cytotoxic therapy, although the transplant procedure itself may also have played a contributory role. 45 In the recently reported French registry analysis, the incidence of MDS or AML in patients with Hodgkin's disease was similar after ASCT or conventional chemotherapy, a finding in keeping with the importance of prior exposure to cytotoxic agents. However, among their ASCT patients, prior splenectomy and the use of PBSC rather than bone marrow as the stem cell source were associated with a higher risk. 44 Other studies have also described a relationship between PBSC grafts and the development of MDS or AML. 42, 43, 46 Further studies are underway to evaluate this possible association, as well as to define other factors that might contribute to the development of MDS or AML post-ASCT. Our single patient with AML after ASCT had received a bone marrow graft; his course was notable for protracted alkylator therapy given in an attempt to prolong a second remission before ASCT became available in our institution.
Less is known about the risk of secondary solid tumors post-ASCT. In the French registry analysis, such tumors were seen in 3.7% of patients with Hodgkin's disease treated with ASCT, and were significantly more common after ASCT compared with conventional therapy. Although radiotherapy has been associated with the development of solid tumors after conventional therapy, [47] [48] [49] no significant risk factors were identified among their ASCT recipients. 44 The low number of events in our series precluded detailed analysis. Due to the long latency period of many of these tumors, ASCT patients will need to be observed for prolonged periods to assess the full impact of this complication.
In summary, among our patients conditioned with higher-dose CBV regimens, less mucosal and hepatic toxicities were observed in those receiving CBVP when compared to CBV. There were no significant differences in the probabilities of NRM or overall PFS. The pulmonary toxicity seen with these higher dose CBV regimens mandates close communication between the patient, referring physician and transplant center after the patient has returned home in order to optimally treat this serious but potentially reversible complication. In addition, ASCT patients require prolonged monitoring to detect the onset of late complications. Strategies to reduce such problems are needed to optimize the results of ASCT in this disease.
